pFUSE-mIgG1e2-Fc1

Plasmid containing a mouse engineered IgG1 Fc region

Catalog # pfc1-mg1e2

For research use only

Version 20K05-MMv43

PRODUCT INFORMATION

Content:

- 20 µg of **pFUSE-mIgG1e2-Fc1** plasmid provided as lyophilized DNA
- 1 ml of Zeocin™ (100 mg/ml)

Storage and Stability:

- Product is shipped at room temperature.
- Lyophilized DNA should be stored at -20°C and is stable 3 months.
- Resuspended DNA should be stored at -20°C and is stable up to 1 year.
- Store Zeocin™ at 4 °C or at -20 °C. The expiry date is specified on the product label.

Quality control:

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

GENERAL PRODUCT USE

pFUSE-Fc is a family of plasmid developed to facilitate the construction of Fc-fusion proteins by fusing the effector region of a protein to the Fc region of an immunoglobulin G (IgG).

pFUSE-Fc plasmids yield high levels of Fc-fusion proteins. The level of expression is usually in the µg/mL range. They can be transfected in a variety of mammalian cells, including myeloma cell lines, CHO cells, monkey COS cells and human embryonic kidney (HEK)293 cells, cells that are commonly used in protein purification systems.

pFUSE-Fc plasmids allow the secretion of Fc-Fusion proteins. As Fc-Fusion proteins are secreted, they can be easily detected in the supernatant of pFUSE-Fc-transfected cells by SDS-PAGE. Furthermore, functional domains can be identified by immunoblotting and ligand blotting.

Fc-Fusion proteins can be easily purified by single-step protein A or protein G affinity chromatography.

InvivoGen provides pFUSE-Fc vectors featuring Fc regions from different species and isotypes. Four murine isotypes are available: IgG1, IgG2a, IgG2b and IgG3. The Fc region mediates effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). In ADCC, the Fc region of an antibody binds to Fc receptors (FcγRs) on the surface of immune effector cells such as natural killers and macrophages, leading to the phagocytosis or lysis of the targeted cells. In CDC, the antibodies kill the targeted cells by triggering the complement cascade at the cell surfaceIgG isoforms exert different levels of effector functions increasing in the order of mIgG1<mIgG3<mIgG2a.

Under certain circumstances, for example when depletion of the target cell is undesirable, abrogating effector functions is required. On the contrary, in the case of antibodies intended for oncology use, increasing effector functions may improve their therapeutic activity[1]. Modifying effector functions can be achieved by engineering the Fc regions to either improve or reduce their binding to FcγRs or the complement factors.

PLASMID FEATURES

• mIgG1e2 Fc (mouse IgG1 engineered Fc): The Fc region comprises the CH2 and CH3 domains of the IgG heavy chain and the hinge region. The hinge serves as a flexible spacer between the two parts of the Fc-fusion protein, allowing each part of the molecule to function independently.
The Fc region of mouse IgG1 mediates low CDC and no ADCC[2]. This engineered form of mIgG1 contains the T252M mutation that increases affinity to protein A, thus facilitating affinity column purification[7].

• hEF1-HTLV prom is a composite promoter comprising the Elongation Factor-1α (EF-1α) core promoter[3] and the R segment and part of the U5 sequence (R-U5') of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat[4]. The EF-1α promoter exhibits a strong activity and yields long lasting expression of a transgene *in vivo*. The R-U5' has been coupled to the EF-1α core promoter to enhance stability of RNA.

• MCS: The multiple cloning site contains several restriction sites that are compatible with many other enzymes, thus facilitating cloning.

• SV40 pAn: the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA[5].

• ori: a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.

• CMV enh / hFerL prom: This composite promoter combines the human cytomegalovirus immediate-early gene 1 enhancer and the core promoter of the human ferritin light chain gene. This ubiquitous promoter drives the expression of the Zeocin™-resistance gene in mammalian cells.

• EM2KC is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*. EM2KC is located within an intron and is spliced out in mammalian cells.

• Zeo: Resistance to Zeocin™ is conferred by the *Sh ble* gene from *Streptoalloteichus hindustanus* The same resistance gene confers selection in both mammalian cells and *E. coli*.

• ßGlo pAn: The human beta-globin 3'UTR and polyadenylation sequence allows efficient arrest of the transgene transcription[6].

1. Carter PJ., 2006. Potent antibody therapeutics by design. Nature Reviews Immunology. Advance online publication.
2. Kipps TJ. et al., 1985. Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J Exp Med. 161(1):1-17.
3. Kim DW *et al*. 1990. Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. 91(2):217-23.
4. Takebe Y. *et al*. 1988. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol. 8(1):466-72.
5. Carswell S. & Alwine JC. 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. Mol Cell Biol. 9(10):4248-58.
6. Yu J. & Russell JE. 2001. Structural and functional analysis of an mRNP complex that mediates the high stability of human beta-globin mRNA. Mol Cell Biol. 21(17):5879-88.
7. Nagaoka M. & Akaike T., 2003 Single amino acid substitution in the mouse IgG1 Fc region induces drastic enhancement of the affinity to protein A. Protein Eng. 16(4):243:245.

TECHNICAL SUPPORT
InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Hong Kong: +852 3622-3480
E-mail: info@invivogen.com

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H_2O. Store resuspended plasmid at -20 °C.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or in other commonly used laboratory *E. coli* strains, such as DH5α.

Zeocin™ usage

This antibiotic can be used for *E. coli* at 25 µg/ml in liquid or solid media and at 50-200 µg/ml to select Zeocin™-resistant mammalian cells.

RELATED PRODUCTS

Product	Catalog Code
Zeocin™	ant-zn-1


pFUSE-mIgG1e2-Fc1
(4125 bp)
mIgG1-Fc [T252M]
PvuI (11)
SgfI (11)
EagI (3962)
NotI (3962)
SwaI (3954)
PacI (3946)
Psp1406I (205)
PvuII (242)
HindIII (246)
AgeI (553)
EcoRI (559)
EcoRV (567)
XhoI (570)
NcoI (578)
BglII (586)
NdeI (607)
BspHI (668)
T252M (669)
BbrPI (695)
PvuII (743)
XmaI (788)
BsrBI (821)
XcmI (984)
BstXI (1249)
NheI (1271)
HpaI (1411)
XmnI (1504)
AseI (1508)
AlwNI (1604)
SspI (1750)
SwaI (1765)
DraIII (1946)
EagI (1961)
XmaI (2204)
BsrBI (2245)
BssHII (2256)
PstI (2414)
AseI (2392)
SacII (2536)
HindIII (2518)
StuI (2620)
BspEI (2676)
SpeI (2783)
Bsp120I (2775)
SnaBI (2913)
NdeI (3017)
BspLU11I (3212)
PacI (3206)
PstI (3199)
SdaI (3199)
AlwNI (3628)
Ori
hEF1-HTLV prom
hinge (frgt)
CH2
CH3
SV40 pAn
ßGlo pAn
Zeo
EM2KC
hFerL prom
CMV enh
100


PvuI (11)
SgfI (11)
1 GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTA
101 GAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCC
HindIII (246)
Psp1406I (205)
PvuII (242)
201 GTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCC
301 GCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACC
401 GGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTT
EcoRI (559)
XhoI (570)
AgeI (553)
EcoRV (567)
NcoI (578)
BglII (586)
501 TCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCACCGGTGAATTCGATATCTCGAGCACCATGGTTAGATCTGGTTGTAAG
1 G C K
T252M (669)
NdeI (607)
BspHI (668)
BbrPI (695)
601 CCTTGCATATGTACAGTCCCAGAAGTATCATCTGTCTTCATCTTCCCCCCAAAGCCCAAGGATGTGCTCATGATTACTCTGACTCCTAAGGTCACGTGTG
4 P C I C T V P E V S S V F I F P P K P K D V L M I T L T P K V T C
PvuII (743)
XmaI (788)
701 TTGTGGTAGACATCAGCAAGGATGATCCCGAGGTCCAGTTCAGCTGGTTTGTAGATGATGTGGAGGTGCACACAGCTCAGACGCAACCCCGGGAGGAGCA
37 V V V D I S K D D P E V Q F S W F V D D V E V H T A Q T Q P R E E Q
BsrBI (821)
801 GTTCAACAGCACTTTCCGCTCAGTCAGTGAACTTCCCATCATGCACCAGGACTGGCTCAATGGCAAGGAGTTCAAATGCAGGGTCAACAGTGCAGCTTTC
70 F N S T F R S V S E L P I M H Q D W L N G K E F K C R V N S A A F
XcmI (984)
901 CCTGCCCCCATCGAGAAAACCATCTCCAAAACCAAAGGCAGACCGAAGGCTCCACAGGTGTACACCATTCCACCTCCCAAGGAGCAGATGGCCAAGGATA
104 P A P I E K T I S K T K G R P K A P Q V Y T I P P P K E Q M A K D
1001 AAGTCAGTCTGACCTGCATGATAACAGACTTCTTCCCTGAAGACATTACTGTGGAGTGGCAGTGGAATGGGCAGCCAGCGGAGAACTACAAGAACACTCA
137 K V S L T C M I T D F F P E D I T V E W Q W N G Q P A E N Y K N T Q
1101 GCCCATCATGGACACAGATGGCTCTTACTTCGTCTACAGCAAGCTCAATGTGCAGAAGAGCAACTGGGAGGCAGGAAATACTTTCACCTGCTCTGTGTTA
170 P I M D T D G S Y F V Y S K L N V Q K S N W E A G N T F T C S V L
BstXI (1249)
NheI (1271)
1201 CATGAGGGCCTGCACAACCACCATACTGAGAAGAGCCTCTCCCACTCTCCTGGTAAATGATCCCAGTGTCGCTAGCTGGCCAGACATGATAAGATACATT
204 H E G L H N H H T E K S L S H S P G K •
1301 GATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCA
HpaI (1411)
1401 ATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGG
AseI (1508)
XmnI (1504)
AlwNI (1604)
1501 TATGGAATTAATTCTAAAATACAGCATAGCAAAACTTTAACCTCCAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCA
1601 GGGGCTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAGATATAGTGTATTTTCCCAAGGTTTGAACTAGCTCTTCATT
SspI (1750)
SwaI (1765)
1701 TCTTTATGTTTTAAATGCACTGACCTCCCACATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGCAATGAAAATAAATGTTTTTTA
1801 TTAGGCAGAATCCAGATGCTCAAGGCCCTTCATAATATCCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAG
DraIII (1946)
EagI (1961)
1901 AAAGCGAGCTTCTAGCTTATCCTCAGTCCTGCTCCTCTGCCACAAAGTGCACGCAGTTGCCGGCCGGGTCGCGCAGGGCGAACTCCCGCCCCCACGGCTG
125 • D Q E E A V F H V C N G A P D R L A F E R G W P Q
2001 CTCGCCGATCTCGGTCATGGCCGGCCCGGAGGCGTCCCGGAAGTTCGTGGACACGACCTCCGACCACTCGGCGTACAGCTCGTCCAGGCCGCGCACCCAC
99 E G I E T M A P G S A D R F N T S V V E S W E A Y L E D L G R V W
2101 ACCCAGGCCAGGGTGTTGTCCGGCACCACCTGGTCCTGGACCGCGCTGATGAACAGGGTCACGTCGTCCCGGACCACACCGGCGAAGTCGTCCTCCACGA
65 V W A L T N D P V V Q D Q V A S I F L T V D D R V V G A F D D E V F


XmaI (2204)
BsrBI (2245)
BssHII (2256)
2201 AGTCCCGGGAGAACCCGAGCCGGTCGGTCCAGAACTCGACCGCTCCGGCGACGTCGCGCGCGGTGAGCACCGGAACGGCACTGGTCAACTTGGCCATGAT
32 D R S F G L R D T W F E V A G A V D R A T L V P V A S T L K A M
AseI (2392)
2301 GGCTCCTCctgtcaggagaggaaagagaagaaggttagtacaattgCTATAGTGAGTTGTATTATACTATGCAGATATACTATGCCAATGATTAATTGTC
PstI (2414)
2401 AAACTAGGGCTGCAgggttcatagtgccacttttcctgcactgccccatctcctgcccacccttcccaggcatagacagtcagtgacttacCAAACTCA
HindIII (2518)
SacII (2536)
2501 CAGGAGGGAGAAGGCAGAAGCTTGAGACAGACCCGCGGGACCGCCGAACTGCGAGGGGACGTGGCTAGGGCGGCTTCTTTTATGGTGCGCCGGCCCTCGG
StuI (2620)
BspEI (2676)
2601 AGGCAGGGCGCTCGGGGAGGCCTAGCGGCCAATCTGCGGTGGCAGGAGGCGGGGCCGAAGGCCGTGCCTGACCAATCCGGAGCACATAGGAGTCTCAGCC
SpeI (2783)
Bsp120I (2775)
2701 CCCCGCCCCAAAGCAAGGGGAAGTCACGCGCCTGTAGCGCCAGCGTGTTGTGAAATGGGGGCTTGGGGGGGTTGGGGCCCTGACTAGTCAAAACAAACTC
2801 CCATTGACGTCAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAG
SnaBI (2913)
2901 CGATGACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGACGTCAAT
NdeI (3017)
3001 AGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGC
PstI (3199)
SdaI (3199)
3101 GTTACTATGGGAACATACGTCATTATTGACGTCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGCCTGCAG
PacI (3206)
BspLU11I (3212)
3201 GTTAATTAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAG
3301 CATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTG
3401 TTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTA
3501 GGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGA
AlwNI (3628)
3601 CACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACG
3701 GCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGC
3801 TGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAG
EagI (3962)
PacI (3946)
SwaI (3954)
NotI (3962)
3901 TGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAAATCAGCGGCCGCAATAAAATATCTTTATTTTCATTACATCTGTG
4001 TGTTGGTTTTTTGTGTGAATCGTAACTAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCA
4101 GGTGCCAGAACATTTCTCTATCGAA